Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Trevi Therapeutics, Inc. (TRVI) is the issuer in an amended ownership report: Frazier Life Sciences Public Fund, L.P. reports shared voting and dispositive power over 7,883,659 common shares, or 5.5%. Frazier Life Sciences X, L.P. reports 365,909 shares (0.3%), and Frazier Life Sciences XI, L.P. reports 1,289,579 shares (0.9%). The percentages are based on 142,475,841 shares outstanding as of July 31, 2026.
The reported share amounts exclude prefunded warrants held by the three funds: respectively, warrants to purchase 10,331,265, 1,458,294, and 2,459,389 shares. Each warrant position is subject to a limit preventing exercise if it would cause the holder, together with affiliates or persons acting as a group, to beneficially own more than 9.99% of shares outstanding immediately after exercise. The FLS X position is also reported by its general-partner entities and members James N. Topper and Patrick J. Heron.
Key Figures
Frazier Life Sciences Public Fund common shares:7,883,659 sharesFrazier Life Sciences X common shares:365,909 sharesFrazier Life Sciences XI common shares:1,289,579 shares+4 more
7 metrics
Frazier Life Sciences Public Fund common shares7,883,659 shares5.5% beneficial ownership; shared voting and dispositive power
Frazier Life Sciences X common shares365,909 shares0.3% beneficial ownership; held directly by Frazier Life Sciences X, L.P.
Frazier Life Sciences XI common shares1,289,579 shares0.9% beneficial ownership; held directly by Frazier Life Sciences XI, L.P.
Common shares outstanding142,475,841 sharesAs of July 31, 2026; basis for the reported ownership percentages
Public Fund prefunded warrants10,331,265 sharesShares purchasable; subject to a 9.99% beneficial-ownership limit after exercise
Frazier Life Sciences X prefunded warrants1,458,294 sharesShares purchasable; subject to a 9.99% beneficial-ownership limit after exercise
Frazier Life Sciences XI prefunded warrants2,459,389 sharesShares purchasable; subject to a 9.99% beneficial-ownership limit after exercise
Key Terms
prefunded warrants, beneficial ownership limitations, shared dispositive power
3 terms
prefunded warrantsfinancial
"certain prefunded warrants to acquire shares of Common Stock"
Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.
beneficial ownership limitationsregulatory
"exercise of which is subject to certain beneficial ownership limitations"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
shared dispositive powerregulatory
"share voting and investment power over the shares of Common Stock held by FLS X"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many TRVI shares does Frazier Life Sciences Public Fund report?
Frazier Life Sciences Public Fund, L.P. reports beneficial ownership of 7,883,659 Trevi Therapeutics common shares, representing 5.5% based on 142,475,841 shares outstanding as of July 31, 2026. It reports shared voting and dispositive power over those shares.
What prefunded warrants do the Frazier funds hold in TRVI?
Frazier Life Sciences Public Fund, L.P. holds prefunded warrants to purchase 10,331,265 shares; Frazier Life Sciences X, L.P. holds warrants to purchase 1,458,294 shares; and Frazier Life Sciences XI, L.P. holds warrants to purchase 2,459,389 shares. Each position may not be exercised if the exercise would result in beneficial ownership above 9.99% of shares outstanding immediately after exercise, including shares held with affiliates or persons acting as a group.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 6)
Trevi Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
89532M101
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
Frazier Life Sciences Public Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
7,883,659.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
7,883,659.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,883,659.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
FHMLSP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
7,883,659.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
7,883,659.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,883,659.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
FHMLSP, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
7,883,659.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
7,883,659.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,883,659.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.5 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
Frazier Life Sciences X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
365,909.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
365,909.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
365,909.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
FHMLS X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
365,909.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
365,909.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
365,909.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
FHMLS X, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
365,909.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
365,909.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
365,909.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
Frazier Life Sciences XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,289,579.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,289,579.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,289,579.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.9 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
FHMLS XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,289,579.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,289,579.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,289,579.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.9 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
FHMLS XI, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,289,579.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,289,579.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,289,579.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
James N. Topper
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
365,909.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
365,909.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
365,909.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
89532M101
1
Names of Reporting Persons
Patrick J. Heron
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
365,909.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
365,909.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
365,909.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Schedule 13G/A.
The percentage listed in row 11 is calculated based on 142,475,841 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Trevi Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
195 Church Street, 16th Floor, New Haven, CT, 06510.
Item 2.
(a)
Name of person filing:
The entities and persons filing this Schedule 13G/A (collectively, the "Reporting Persons") are:
Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron" and together with Topper, the "Members")
(b)
Address or principal business office or, if none, residence:
The address and principal business office of the Reporting Persons is:
c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite 200B
Palo Alto, CA 94304
(c)
Citizenship:
The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G/A is incorporated by reference.
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP No.:
89532M101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
FLSPF directly holds 7,883,659 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF.
FLS X directly holds 365,909 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X.
FLS XI directly holds 1,289,579 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI.
Consistent with prior reporting, the above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain prefunded warrants to acquire shares of Common Stock (the "Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, (i) FLSPF holds Warrants to purchase 10,331,265 shares of Common Stock, (ii) FLS X holds Warrants to purchase 1,458,294 shares of Common Stock, and (iii) FLS XI holds Warrants to purchase 2,459,389 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.
(b)
Percent of class:
The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Frazier Life Sciences Public Fund, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:
11/16/2026
FHMLSP, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:
11/16/2026
FHMLSP, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:
11/16/2026
Frazier Life Sciences X, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:
11/16/2026
FHMLS X, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:
11/16/2026
FHMLS X, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date:
11/16/2026
Frazier Life Sciences XI, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:
11/16/2026
FHMLS XI, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:
11/16/2026
FHMLS XI, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:
11/16/2026
James N. Topper
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney
Date:
11/16/2026
Patrick J. Heron
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney
Date:
11/16/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G/A filed on May 15, 2025)